Drug intelligence / Profile preview

TAK-915 + midazolam

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

**TAK-915 + midazolam** is a combination of TAK-915, an investigational selective phosphodiesterase 2A (PDE2A) inhibitor, and midazolam, a well-known benzodiazepine. This combination is used in clinical pharmacology studies to evaluate potential pharmacokinetic drug-drug interactions, specifically to assess whether TAK-915 affects the metabolism of midazolam, a probe substrate for the CYP3A4 enzyme. TAK-915 is under development for improving cognitive function and treating cognitive impairments, with midazolam acting as a sensitive marker for hepatic enzyme activity. TAK-915 is being developed by Takeda.

Targets

PDE2 (Phosphodiesterase 2)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on TAK-915 + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-915 + midazolam.

Explore the full profile